Tsuyoshi Yanagimachi

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice

Yasutaka Takeda, Yukihiro Fujita, Jun Honjo et al. · Diabetologia · 2011 · 119 citations · Full text

Insulin Signaling, Biochemistry, Medicine +9

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda et al. · Molecular Metabolism · 2017 · 37 citations · Full text

Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8

Yumi Takiyama, Toshihiro Sera, Masanori Nakamura et al. · EBioMedicine · 2018 · 32 citations · Full text

Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice

Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda et al. · Diabetologia · 2015 · 27 citations · Full text

Metabolic Syndrome, Insulin Signaling, Diabetes Management +13

Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial

Kayo Horibe, Katsutaro Morino, Itsuko Miyazawa et al. · Diabetes Research and Clinical Practice · 2022 · 25 citations

Metabolic Syndrome, Diabetes Management, Sglt2 Inhibitor +6